Office AddressDepartment of Pathology
3990 John R. Road
Harper University Hospital, Detroit Medical Center
Detroit, MI 48202
Administrative ContactLydia Cuper
Phone: (313) 745-2520
Phone: (313) 577-1102
Chairman, Pathology Department
Specialist-in-chief of Pathology, DMC
M.D. (1980): University of Damascus, Damascus, Syria
1985-1987: Harper Hospital, Wayne State University School of Medicine, Detroit, MI, USA, in Surgical Pathology
Areas of InterestProstate Cancer, Surgical pathology, urologic pathology, head and neck pathology
Dr. Sakr has been interested in the histopathological and biological traits of preneoplastic changes of the prostate. His work contributed to a current consensus that high grade prostatic intraepithelial neoplasm is a precursor of prostate adenocarcinoma. Dr. Sakr has been actively involved in numerous clinical trials as an expert pathologist. In other clinical studies, Dr. Sakr is interested in evaluating genetic changes and expression profiling as markers for cancer diagnosis and prognosis. In addition, Dr. Sakr is an active investigator on several funded basic research projects on the underlying molecular mechanism of prostate tumor progression and metastasis.
Urological malignancies, preneoplastic diseases, prostate, molecular markers, and cancer biology
1982-1985: Booth Memorial Hospital, New York University, New York, NY, USA
1. Sakr WA, 1998, High‑grade prostatic intraepithelial neoplasia: additional links to a potentially more aggressive prostate cancer? [editorial; comment] J Natl Cancer Inst; 90:486‑487.
2. Yin, S, Li, X, Meng, Y. Finley, RL Jr, Sakr, W, Yang, H, Reddy, N, and Sheng, S, 2005, Tumor suppressive maspin regulates cell response to oxidative stress by direct Interaction with glutathione s-transferase, J. Biol. Chem. 280: 4985-96.
3. Marshall, JR, Sakr, WA, Wood, D, Berry, D, Tangen, C, Parker, F, Thompson, I, Lippman, SM, Lieberman, R, Alberts, D, Jarrard, D, Coltman, C, Greenwald, P, Minasian, L, and Crawford, ED, 2006, Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasia, Cancer Epidemiology Biomarkers & Prevention, 15: 1479-84.
4. Li, X, Yin, S, Sakr, W, Meng, Y, Zhao, Z, and Sheng, S, 2006, Endogenous inhibition of histone deacetylase 1 by tumor suppressive maspin, Cancer Res, 66: 9330-7.
5. Rahman KM, Banerjee S, Ali S, Ahmad A, Wang Z, Kong D and Sakr W, 2009, DIM enhances Taxotere-induced apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation, Cancer Res, 69: 4468-75.